July 2025 – Page 10

RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief

4 months ago talkbio0Tagged Buckham, Changing, CHARGE Syndrome, chief of, federal, Hannah Anderson, Health Policy, Heather Flick Melanson, Leadership, RFK Jr., Shakeup, Staff, TMEM79 gene

RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy

RFK Jr. Fires Top HHS Leadership in Major Department Shakeup

4 months ago talkbio0Tagged Buckham, CHARGE Syndrome, Hannah Anderson, Health Policy, Heather Flick Melanson, Leadership, RFK Jr., Shakeup, Staff, TMEM79 gene, White House liaison

RFK Jr.; HHS; leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; health policy; White House liaison

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

4 months ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

4 months ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

RFK Jr. Removes Top HHS Aides in Major Leadership Shakeup

4 months ago talkbio0Tagged Buckham, chief of, Hannah Anderson, Health, Heather Flick Melanson, Leadership, Policy, reshuffle, RFK Jr., Shakeup, Social Welfare, Staff, TMEM79 gene, Trump loyalists

RFK Jr.; Health and Human Services; leadership reshuffle; chief of staff; Matt Buckham; Heather Flick Melanson; Hannah Anderson; Trump loyalists; policy shakeup

Outsmarting Data Bottlenecks in Pharma: The Clinical Terminology Advantage

4 months ago talkbio0Tagged Artificial Intelligence, clinical terminology, data bottlenecks, Data Integration, Drug Industry, Interoperability, Pharma, Regulatory Compliance

data bottlenecks; clinical terminology; pharmaceutical industry; data integration; interoperability; regulatory compliance; AI in pharma; patient outcomes

Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies

4 months ago talkbio0Tagged Autoimmune Diseases, CAN10, Cantargia, global commercialization, Hidradenitis Suppurativa, IL1RAP antibodies, milestone payments, Otsuka Pharmaceutical, Systemic Scleroderma

Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization

Vertex, NHS England Finalize Reimbursement Deal for CF Drug Alyftrek

4 months ago talkbio0Tagged ALYFTREK, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation, Health care facility, NHS England, Nitroglycerin/Sodium Citrate/Ethanol Solution, Reimbursement, triple therapy, UK

Vertex; NHS England; Alyftrek; cystic fibrosis; reimbursement agreement; triple therapy; CFTR gene mutation; NICE; UK healthcare

Recent Developments in Building Measurable Patient Support Programs (2025)

4 months ago talkbio0Tagged 2025, care activity, collaborative healthcare, Efficiency, Financial cost, measurable outcomes, Medicare reforms, Programs - Publication Format, trends qualifier

patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care

FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

4 months ago talkbio0Tagged Advisory Committees, Blenrep, Drug Approval, Eye, Eye safety, Multiple Myeloma, relapsed/refractory multiple myeloma, SmithKline Beecham, Toxicity aspects, United States, United States Food and Drug Administration

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma